GAD2 and type 1 diabetes mellitus: GAD65-immunized HLA DR3-DQ2 T1D patients also had greater GAD65-stimulated PBMC proliferation as well as IL-10 and IL-13 section compared with those negative for HLA DR3-DQ2 or patients in the placebo group [6].